Mirati Therapeutics
Market Cap
US$10.8b
Last Updated
2021/01/17 00:34 UTC
Data Sources
Company Financials +
Executive Summary
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Mirati Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MRTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: MRTX's weekly volatility (6%) has been stable over the past year.
Market Performance
7 Day Return
-1.4%
MRTX
3.5%
US Biotechs
-1.0%
US Market
1 Year Return
121.0%
MRTX
36.8%
US Biotechs
19.6%
US Market
Return vs Industry: MRTX exceeded the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: MRTX exceeded the US Market which returned 19.6% over the past year.
Shareholder returns
| MRTX | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.4% | 3.5% | -1.0% |
| 30 Day | -10.2% | 4.5% | 2.2% |
| 90 Day | 8.0% | 19.2% | 11.5% |
| 1 Year | 121.0%121.0% | 39.0%36.8% | 22.3%19.6% |
| 3 Year | 737.8%737.8% | 30.5%23.6% | 45.3%35.7% |
| 5 Year | 758.2%758.2% | 43.9%33.0% | 124.8%99.8% |
Long-Term Price Volatility Vs. Market
How volatile is Mirati Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall St
We're Hopeful That Mirati Therapeutics (NASDAQ:MRTX) Will Use Its Cash Wisely1 month ago | Simply Wall St
A Look At The Intrinsic Value Of Mirati Therapeutics, Inc. (NASDAQ:MRTX)2 months ago | Simply Wall St
Revenue Downgrade: Here's What Analysts Forecast For Mirati Therapeutics, Inc. (NASDAQ:MRTX)Valuation
Is Mirati Therapeutics undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MRTX ($214.47) is trading below our estimate of fair value ($1011.52)
Significantly Below Fair Value: MRTX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MRTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MRTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MRTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MRTX is overvalued based on its PB Ratio (17.4x) compared to the US Biotechs industry average (4.2x).
Next Steps
Future Growth
How is Mirati Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
56.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MRTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MRTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MRTX's revenue (66.1% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: MRTX's revenue (66.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRTX is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Mirati Therapeutics performed over the past 5 years?
-34.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRTX is currently unprofitable.
Growing Profit Margin: MRTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MRTX is unprofitable, and losses have increased over the past 5 years at a rate of 34.9% per year.
Accelerating Growth: Unable to compare MRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: MRTX has a negative Return on Equity (-59.76%), as it is currently unprofitable.
Next Steps
Financial Health
How is Mirati Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: MRTX's short term assets ($595.4M) exceed its short term liabilities ($67.4M).
Long Term Liabilities: MRTX's short term assets ($595.4M) exceed its long term liabilities ($1.5M).
Debt to Equity History and Analysis
Debt Level: MRTX is debt free.
Reducing Debt: MRTX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MRTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MRTX has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 29.1% each year.
Next Steps
Dividend
What is Mirati Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MRTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MRTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MRTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Charles Baum (62 yo)
8.17yrs
Tenure
US$8,484,393
Compensation
Dr. Charles M. Baum, M.D., Ph.D. served as a Director at Immunomedics, Inc. since February 23, 2019 until October 23, 2020. Dr. Baum currently serves as Director of BCTG Acquisition Corp. He has been the C...
CEO Compensation Analysis
Compensation vs Market: Charles's total compensation ($USD8.48M) is about average for companies of similar size in the US market ($USD10.56M).
Compensation vs Earnings: Charles's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.17yrs | US$8.48m | 0.094% $ 10.2m | |
| Chief Scientific Officer & Executive VP | 7yrs | US$3.29m | 0.053% $ 5.7m | |
| Executive VP | 1yr | no data | 0.047% $ 5.1m | |
| Senior VP of Technical Operation & Chief Accounting Officer | 1yr | no data | 0.015% $ 1.6m | |
| Director of Investor Relations & Corporate Communications | no data | no data | no data | |
| VP, General Counsel & Corporate Secretary | 1yr | no data | no data | |
| Senior VP & Head of Drug Discovery | 3yrs | no data | no data | |
| Senior Vice President of Technical Operations | 1.67yrs | no data | no data | |
| Executive VP & Chief Commercial Officer | 1yr | no data | 0.039% $ 4.2m | |
| VP & Head of Medical Affairs | 0.75yr | no data | no data | |
| VP & Head of Corporate Affairs | 0.75yr | no data | no data | |
| Head of Regulatory Affairs and VP of Regulatory Affairs & Quality Assurance | 7yrs | no data | no data |
1.0yrs
Average Tenure
52yo
Average Age
Experienced Management: MRTX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.17yrs | US$8.48m | 0.094% $ 10.2m | |
| Independent Director | 6.17yrs | US$589.67k | 0.0045% $ 484.2k | |
| Independent Director | 8.92yrs | US$603.17k | 0.0040% $ 429.2k | |
| Independent Director | 4.33yrs | US$606.67k | 0.0040% $ 429.2k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of the Board | 1.92yrs | US$2.65m | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.08yrs | US$579.67k | 0.078% $ 8.4m | |
| Independent Director | 7.33yrs | US$605.17k | 0.0040% $ 429.2k | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Independent Director | 2.08yrs | US$592.67k | 0% $ 0 |
4.3yrs
Average Tenure
62yo
Average Age
Experienced Board: MRTX's board of directors are considered experienced (4.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MRTX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.3%.
Top Shareholders
Company Information
Mirati Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Mirati Therapeutics, Inc.
- Ticker: MRTX
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$10.784b
- Shares outstanding: 50.28m
- Website: https://www.mirati.com
Number of Employees
Location
- Mirati Therapeutics, Inc.
- 9393 Towne Centre Drive
- Suite 200
- San Diego
- California
- 92121
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MRTX | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Jun 2004 |
| 26M | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jun 2004 |
Biography
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/17 00:34 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.